Wild Bird Therapeutics has been selected to join the IGNITE programme from Hong Kong-Shenzhen Innovation and Technology Parks (HSITP), supporting the company’s international expansion and the development of its AI-enabled oncology and ADC innovation platform within Hong Kong’s biotechnology ecosystem.